Advertisement
Home »

Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials.

Sep 09, 2024

ABOUT THE EXPERTS

  • Martin Haluzík

    Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.

    Mohammed E Al-Sofiani

    Department of Internal Medicine, King Saud University, Riyadh, Saudi Arabia.

    Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, Maryland, USA.

    Alice Y Y Cheng

    Department of Medicine, University of Toronto, Toronto, Canada.

    Felipe Lauand

    Sanofi, Paris, France.

    Lydie Melas-Melt

    IVIDATA Life Sciences, Levallois-Perret, France.

    Julio Rosenstock

    Velocity Clinical Research at Medical City Dallas, Dallas, Texas, USA.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement